Effect of Hirudin versus Heparin on Hemocompatibility of Blood Contacting Biomaterials: An in Vitro Study

Abstract

Hirudin serves as an alternative anticoagulant for extracorporeal blood circulation. Comparing anticoagulation with hirudin (2.5 or 5.0 μg/mL) and heparin (2.0 or 4.0 IU/mL) human blood was circulated in a modified “Chandler System” using PVC-tubes for 2 hours at 37°C. Activation of coagulation (thrombin-antithrombin III-complex, prothrombin fragment 1+2 and D-Dimer), platelet (platelet factor 4 - PF4) and complement systems was analyzed. Both heparin concentrations and 5.0 μg/dL hirudin led to as significantly less activated plasmatic coagulation as 2.5 μg/dL hirudin. Decreased levels of PF4 and anaphylatoxin C5a (P&0.05) as well as terminal complement complex demonstrated improved hemocompatibility after anticoagulation with heparin in contrast to hirudin. Because initial coagulation cascade, platelet activation and complement activation is less influenced by hirudin than by heparin, hemocompatibility is more dependent on the characteristics of the biomaterials used. This predestines hirudin as anticoagulant for in vitro studies analyzing hemocompatibility of biomaterials or surface modifications.